$ANAB Q2 '26 Earnings Results & Recap
• Reported GAAP EPS of $5.11 up 481.34% YoY
• Reported revenue of $27.49M up 23.50% YoY
• AnaptysBio continues to expect to achieve $390M in annualized Jemperli royalties payable to the company as early as 2029 at GSKs peak monotherapy sales guidance of $2.7B.